Axsome Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $118,766 | $104,762 | $87,166 | $74,999 |
Gross Profit | 108,252 | 96,325 | 79,111 | 66,871 |
EBITDA | -70,544 | -60,563 | -78,046 | -65,444 |
EBIT | -72,617 | -62,624 | -80,039 | -67,275 |
Net Income | -74,912 | -64,602 | -79,345 | -68,357 |
Net Change In Cash | 118,766 | 104,762 | 87,166 | 74,999 |
Free Cash Flow | -26,232 | -18,481 | -30,162 | -53,565 |
Cash | 315,353 | 327,341 | 315,657 | 331,441 |
Basic Shares | 47,914 | 48,140 | 47,573 | 47,393 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $385,693 | $270,600 | $50,037 | $8,819 |
Gross Profit | 352,390 | 244,535 | 44,839 | -1,155 |
EBITDA | -280,562 | -224,991 | -174,234 | -123,551 |
EBIT | -231,825 | -179,799 | -124,706 | |
Net Income | -287,216 | -239,238 | -197,766 | -134,943 |
Net Change In Cash | 385,693 | 270,600 | 50,037 | 8,819 |
Cost of Revenue | -97,403 | |||
Free Cash Flow | -128,680 | -145,662 | -117,212 | -108,533 |
Cash | 315,353 | 386,193 | 200,841 | 86,472 |
Basic Shares | 47,914 | 45,425 | 40,655 | 37,618 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$1.54 |
2024-09-30 | -$1.34 |
2024-06-30 | -$1.67 |
2024-03-31 | -$1.44 |
